APA (7th ed.) Citation

Wang, Y., Lin, C., Su, Y., & Teng, C. J. (2025). Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A systemic review and meta-analysis. Hematology, 30(1), 1. https://doi.org/10.1080/16078454.2025.2462249

Chicago Style (17th ed.) Citation

Wang, Yin-Che, Cheng-Hsien Lin, Yu-Chen Su, and Chieh-Lin Jerry Teng. "Bortezomib, Thalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-analysis." Hematology 30, no. 1 (2025): 1. https://doi.org/10.1080/16078454.2025.2462249.

MLA (9th ed.) Citation

Wang, Yin-Che, et al. "Bortezomib, Thalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-analysis." Hematology, vol. 30, no. 1, 2025, p. 1, https://doi.org/10.1080/16078454.2025.2462249.